SAN DIEGO (April 2, 2018) – 10xBio, LLC, a privately-held biotechnology company, announced today that the Investigational New Drug “IND” application for 10XB101 has been accepted by the U.S. FDA. The company expects to initiate Phase 1b/2a testing immediately. This testing will establish the safety and tissue responses of the injectable drug candidate for dermatologic applications.
John Dobak, M.D., the company’s Chairman commented, “The opening of an IND is always an important milestone for a new therapeutics company. I would like to thank our development partner, Therapeutics, Inc., who put together an outstanding application and shepherded it through the division of dermatology.”
Dan Piacquadio, M.D., the President and CEO of Therapeutics, Inc. commented, “We are pleased to be partnering with 10XBio on this development program. We believe 10XB101 may offer significant improvements over existing therapy.”
We are a biotechnology company that focuses on new uses for existing therapies and technologies. This strategy allows us to build on existing safety profiles and leverage known mechanisms of action, resulting in a streamlined development and regulatory process. Our most advanced asset, 10XB101, is a pharmaceutical product that addresses unmet needs in dermatologic medicine. For more information, visit us at www.10xBio.com.
John Dobak, M.D.